Payment overview · 2025
General Payments
$985.59
23 reported records · 10 companies
Healthcare provider profile · identity verified
Eric Lough, MD
Allopathic & Osteopathic Physicians|Internal Medicine · VENICE, FL · NPI 1437255916
Verified facts
What the public records show
CMS Open Payments records show Eric Lough, MD received $985.59 in general payments during 2025 across 23 reported records.
Cleerly, Inc. accounted for 43.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Cleerly, Inc. | Unresolved — no canonical attribution shown | $428.28 | 43.5% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $157.52 | 16.0% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $98.48 | 10.0% | 6 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $95.67 | 9.7% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $49.03 | 5.0% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $46.87 | 4.8% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $36.15 | 3.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $35.73 | 3.6% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.32 | 2.3% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.54 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $985.59 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cleerly Ischemia Normalized: cleerly ischemia |
Device | Cleerly, Inc. | $428.28 | 2 | 2025 |
Source payment records
|
|||||
| Cleerly Labs Normalized: cleerly labs |
Device | Cleerly, Inc. | $428.28 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $142.92 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $135.64 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $121.04 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $98.48 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $98.48 | 6 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $67.99 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $49.03 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $46.87 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $36.15 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $27.68 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.32 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.52 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.52 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 520 | 158 |
| Amlodipine Besylate | Amlodipine Besylate | 325 | 93 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 287 | 91 |
| Lisinopril | Lisinopril | 286 | 89 |
| Levothyroxine Sodium | Levothyroxine Sodium | 275 | 72 |
| Omeprazole | Omeprazole | 212 | 63 |
| Metoprolol Succinate | Metoprolol Succinate | 201 | 62 |
| Losartan Potassium | Losartan Potassium | 197 | 58 |
| Simvastatin | Simvastatin | 193 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 166 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 138 | 49 |
| Metformin Hcl | Metformin Hcl | 132 | 43 |
| Eliquis | Apixaban | 129 | 36 |
| Gabapentin | Gabapentin | 129 | 38 |
| Potassium Chloride | Potassium Chloride | 122 | 37 |
| Methylprednisolone | Methylprednisolone | 114 | 97 |
| Valsartan | Valsartan | 112 | 32 |
| Bupropion Xl | Bupropion Hcl | 102 | 30 |
| Pioglitazone Hcl | Pioglitazone Hcl | 98 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 93 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 91 | 39 |
| Mirtazapine | Mirtazapine | 89 | 31 |
| Meloxicam | Meloxicam | 88 | 29 |
| Allopurinol | Allopurinol | 87 | 29 |
| Sertraline Hcl | Sertraline Hcl | 87 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 80 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 77 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 74 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 71 | 23 |
| Finasteride | Finasteride | 65 | 18 |
| Carvedilol | Carvedilol | 62 | 19 |
| Metformin Hcl Er | Metformin Hcl | 62 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 59 | 24 |
| Furosemide | Furosemide | 57 | 18 |
| Spironolactone | Spironolactone | 56 | 20 |
| Buspirone Hcl | Buspirone Hcl | 55 | 18 |
| Bumetanide | Bumetanide | 53 | 14 |
| Trazodone Hcl | Trazodone Hcl | 53 | 16 |
| Glimepiride | Glimepiride | 52 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 51 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 49 | 14 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 44 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 41 | 35 |
| Ezetimibe | Ezetimibe | 40 | 14 |
| Montelukast Sodium | Montelukast Sodium | 40 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 36 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 36 | 11 |
| Famotidine | Famotidine | 35 | 13 |
| Prednisone | Prednisone | 35 | 20 |
| Atenolol | Atenolol | 34 | suppressed |
| Xarelto | Rivaroxaban | 32 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 31 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 22 |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Celecoxib | Celecoxib | 27 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 24 |
| Valacyclovir | Valacyclovir Hcl | 27 | 12 |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 24 | 18 |
| Cephalexin | Cephalexin | 23 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | 16 |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 22 | 11 |
| Primidone | Primidone | 22 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Jardiance | Empagliflozin | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 17 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Alprazolam | Alprazolam | 17 | suppressed |
| Azithromycin | Azithromycin | 17 | 17 |
| Lovastatin | Lovastatin | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Minoxidil | Minoxidil | 15 | suppressed |
| Ozempic | Semaglutide | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Ssd | Silver Sulfadiazine | 15 | 11 |
| Sulindac | Sulindac | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Silver Sulfadiazine | Silver Sulfadiazine | 12 | 11 |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $985.59 · 23 records | Cleerly, Inc. | AIRSUPRA, BREZTRI, CAPVAXIVE, Cleerly Ischemia, Cleerly Labs, Cologuard Collection Kit, FARXIGA, FREESTYLE LIBRE 3, Korlym, LEQVIO, OTEZLA, Ozempic, REPATHA, Rybelsus, The Cologuard Plus Collection Kit, XIFAXAN | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error